PW showed Amryt just 3 weeks ago in the investor presentations in Dusseldorf and Frankfurt. A couple of years back Amryt was taken over by an Italian firm Chiesi for about $1.25 Billion USD (~$2 Billion AUD, CUV equivalent ~$40 AUD per share). Amryt had some approved drugs in very rare diseases but was posting some solid losses unlike Clinuvel with their growing profits and massive growing cash pile. Interesting article below from seeking alpha. Also interesting that PW showed Amryt on the investor presentation, many similarities between these companies, Amryt was also treating a rare and terrible skin disease. IMO Clinuvel is superior and has more blockbuster potential than Amryt ever did.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)